Anavex Life Sciences Corp (AVXL)

[falconer66a]

Anavex 3-71 Works in Transgenic Alzheimer’s Rats

RESULTS:
AF710B [Anavex 3-71] long-term treatment reverted the cognitive deficits associated with advanced Alzheimer-like amyloid neuropathology in Tg rats [transgenic, genetically modified rats with human Alzheimer’s]. These effects were accompanied by reductions in amyloid pathology and markers of neuroinflammation and increases in amyloid cerebrospinal fluid clearance and levels of a synaptic marker. Importantly, these effects were maintained following a 5-week interruption of the treatment.

https://www.ncbi.nlm.nih.gov/pubmed/29291374

Well, Anavex 3-71 induces favorable treatment responses for most of the Alzheimer’s symptoms: a) reversion (back toward normal) of cognition (thinking) deficits related to, associated with Alzheimer’s, b) reduced pathology (symptoms) caused by amyloid plaques (just what the anti-amyloid people have been unsuccessfully searching for), c) clearance of waste amyloid proteins in the cerebrospinal fluid (a major diagnostic indication of treatment efficacy), and d) retained, continued maintenance of these good outcomes following treatment termination (for 5-weeks).

A rat living to 30 months (120 weeks) is equivalent to a human at 75 years (a not-uncommon age for Alzheimer’s). With this, five rat-weeks is roughly equivalent to three human years. If the rat results are proportional to those in humans, Alzheimer’s patients treated to stable symptomatic resolution would be expected to maintain those good outcomes for at least three years following treatment termination. http://www.ratbehavior.org/RatYears.htm

Anavex 3-71 is a significant, if yet unrealized corporate asset; another promising, proprietary Alzheimer’s treatment drug.

Wanna bet it works in humans just as it does in transgenic Alzheimer’s rats? No one should (yet) place that bet. Will take real human trials. But a good number of us, based on similar preclinical murine studies, have already placed our bets on Anavex 2-73. We’ve taken AVXL positions, and await the upcoming clinical trials. All of the pre-clinical murine studies, similar to the one above, show it will work in humans.